04:56 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Syntimmune reports Phase Ia data for autoimmune disease candidate

Syntimmune Inc. (Waltham, Mass.) reported data from a Phase Ia trial in 31 healthy volunteers showing that single ascending doses of IgG-mediated autoimmune disease candidate IV SYNT001 were well tolerated with no serious adverse events...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
19:10 , Jul 6, 2017 |  BioCentury  |  Finance

Planting seeds

With a $1.5 billion open-ended fund, Apple Tree Partners is plowing large sums into a handful of translational start-ups with the goal of eventually having at least one portfolio company grow into a commercial-stage large...
17:47 , Jun 21, 2017 |  BC Extra  |  Financial News

Autoimmune play Syntimmune raises $50M

Autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million in a series B round. Existing investor Apple Tree Partners invested $48 million to lead the round. Also participating were existing investors Partners Innovation...
19:06 , Jan 6, 2017 |  BioCentury  |  Emerging Company Profile

Gobbling globulins

Syntimmune Inc. is targeting a receptor that mediates the life span and activity of immunoglobulin G to control autoimmune disease more precisely and potentially more safely than broadly acting agents. The company aims to differentiate...
01:24 , Mar 23, 2016 |  BC Extra  |  Financial News

Syntimmune raises second series A tranche

Syntimmune Inc. (New York, N.Y.) raised $10 million in the second tranche of a planned $26 million series A round co-led by Apple Tree Partners and the Baxalta Ventures arm of Baxalta Inc. (NYSE:BXLT). Partners...